Ipilimumab vs Tilmanocept
Ipilimumab vs Tilmanocept: Overview
This comparison examines the pharmacological differences between Ipilimumab and Tilmanocept.
Mechanism of Action
Ipilimumab: Fully human anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 inhibitory signaling.
Pharmacokinetics
Half-life: Ipilimumab — 14.7 days.
Chemical Properties
Type: Ipilimumab — Antibody; Tilmanocept — Small molecule.